|
1
|
Ghaneh P, Smith R, Tudor-Smith C, Raraty M
and Neoptolemos JP: Neoadjuvant and adjuvant strategies for
pancreatic cancer. Eur J Surg Oncol. 34:297–305. 2008. View Article : Google Scholar
|
|
2
|
Sugimura T, Terada M, Yokota J, Hirohashi
S and Wakabayashi K: Multiple genetic alterations in human
carcinogenesis. Environ Health Perspect. 98:5–12. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Neoptolemos JP, Urrutia R, Abbruzzese JL
and Büchler MW: Pancreatic Cancer. Chapter. 21:498–505. 2010.
|
|
4
|
Rafael S, Veganzones S, Vidaurreta M, de
la Orden V and Maestro ML: Effect of β-catenin alterations in the
prognosis of patients with sporadic colorectal cancer. J Cancer Res
Ther. 10:591–596. 2014.PubMed/NCBI
|
|
5
|
López-Casas PP and López-Fernández LA:
Gene-expression profiling in pancreatic cancer. Expert Rev Mol
Diagn. 10:591–601. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Maitra A, Kern SE and Hruban RH: Molecular
pathogenesis of pancreatic cancer. Best Pract Res Clin
Gastroenterol. 20:211–226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Q and Xu W: Novel anticancer targets
and drug discovery in post genomic age. Curr Med Chem Anticancer
Agents. 5:53–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Morris JP IV, Wang SC and Hebrok M: KRAS,
Hedgehog, Wnt and the twisted developmental biology of pancreatic
ductal adenocarcinoma. Nat Rev Cancer. 10:683–695. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Banerjee S, Ahmad A, Li Y, Azmi
AS, Gunn JR, Kong D, Bao B, Ali S, Gao J, et al: Activated K-ras
and INK4a/Arf deficiency cooperate during the development of
pancreatic cancer by activation of Notch and NF-κB signaling
pathways. PLoS One. 6:e205372011. View Article : Google Scholar
|
|
11
|
Lauth M and Toftgård R: Hedgehog signaling
and pancreatic tumor development. Adv Cancer Res. 110:1–17. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang da W, Sherman BT and Lempicki RA:
Bioinformatics enrichment tools: paths toward the comprehensive
functional analysis of large gene lists. Nucleic Acids Res.
37:1–13. 2009. View Article : Google Scholar :
|
|
13
|
Biankin AV, Waddell N, Kassahn KS, Gingras
MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J,
et al: Pancreatic cancer genomes reveal aberrations in axon
guidance pathway genes. Nature. 491:399–405. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shain AH, Salari K, Giacomini CP and
Pollack JR: Integrative genomic and functional profiling of the
pancreatic cancer genome. BMC Genomics. 14:6242013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mohr S, Leikauf GD, Keith G and Rihn BH:
Microarrays as cancer keys: An array of possibilities. J Clin
Oncol. 20:3165–3175. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chang ZY, Sun R, Ma YS, Fu D, Lai XL, Li
YS, Wang XH, Zhang XP, Lv ZW, Cong XL, et al: Differential gene
expression of the key signalling pathway in para-carcinoma,
carcinoma and relapse human pancreatic cancer. Cell Biochem Funct.
32:258–267. 2014. View
Article : Google Scholar
|
|
18
|
Nakamura T, Furukawa Y, Nakagawa H,
Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N,
Miyamoto M, et al: Genome-wide cDNA microarray analysis of gene
expression profiles in pancreatic cancers using populations of
tumor cells and normal ductal epithelial cells selected for purity
by laser microdissection. Oncogene. 23:2385–2400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Backman V, Wallace MB, Perelman LT, Arendt
JT, Gurjar R, Müller MG, Zhang Q, Zonios G, Kline E, McGilligan JA,
et al: Detection of preinvasive cancer cells. Nature. 406:35–36.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schernhammer E, Wolpin B, Rifai N,
Cochrane B, Manson JA, Ma J, Giovannucci E, Thomson C, Stampfer MJ
and Fuchs C: Plasma folate, vitamin B6, vitamin B12, and
homocysteine and pancreatic cancer risk in four large cohorts.
Cancer Res. 67:5553–5560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Johansson M, Relton C, Ueland PM, Vollset
SE, Midttun Ø, Nygård O, Slimani N, Boffetta P, Jenab M,
Clavel-Chapelon F, et al: Serum B vitamin levels and risk of lung
cancer. JAMA. 303:2377–2385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu W, Kang S and Zhang D: Association of
vitamin B6, vitamin B12 and methionine with risk of breast cancer:
A dose-response meta-analysis. Br J Cancer. 109:1926–1944. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dubois EL: The effect of the L. E. cell
test on the clinical picture of systemic lupus erythematosus. Ann
Intern Med. 38:1265–1294. 1953. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smedby KE, Hjalgrim H, Askling J, Chang
ET, Gregersen H, Porwit-MacDonald A, Sundström C, Akerman M, Melbye
M, Glimelius B, et al: Autoimmune and chronic inflammatory
disorders and risk of non-Hodgkin lymphoma by subtype. J Natl
Cancer Inst. 98:51–60. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Björnådal L, Löfström B, Yin L, Lundberg
IE and Ekbom A: Increased cancer incidence in a Swedish cohort of
patients with systemic lupus erythematosus. Scand J Rheumatol.
31:66–71. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cibere J, Sibley J and Haga M: Systemic
lupus erythematosus and the risk of malignancy. Lupus. 10:394–400.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pettersson T, Pukkala E, Teppo L and
Friman C: Increased risk of cancer in patients with systemic lupus
erythematosus. Ann Rheum Dis. 51:437–439. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bernatsky S, Ramsey-Goldman R, Rajan R,
Boivin JF, Joseph L, Lachance S, Cournoyer D, Zoma A, Manzi S,
Ginzler E, et al: Non-Hodgkin's lymphoma in systemic lupus
erythematosus. Ann Rheum Dis. 64:1507–1509. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ramsey-Goldman R, Mattai SA, Schilling E,
Chiu YL, Alo CJ, Howe HL and Manzi S: Increased risk of malignancy
in patients with systemic lupus erythematosus. J Investig Med.
46:217–222. 1998.PubMed/NCBI
|
|
30
|
Bernatsky S, Ramsey-Goldman R, Isenberg D,
Isenberg D, Rahman A, Dooley MA, Sibley J, Boivin JF, Joseph L,
Armitage J, et al: Hodgkin's lymphoma in systemic lupus
erythematosus. Rheumatology (Oxford). 46:830–832. 2007. View Article : Google Scholar
|
|
31
|
Landgren O, Engels EA, Pfeiffer RM,
Gridley G, Mellemkjaer L, Olsen JH, Kerstann KF, Wheeler W,
Hemminki K, Linet MS, et al: Autoimmunity and susceptibility to
Hodgkin lymphoma: A population-based case-control study in
Scandinavia. J Natl Cancer Inst. 98:1321–1330. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gayed M, Bernatsky S, Ramsey-Goldman R,
Clarke A and Gordon C: Lupus and cancer. Lupus. 18:479–485. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bernatsky S, Boivin JF, Joseph L, Manzi S,
Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, et
al: Mortality in systemic lupus erythematosus. Arthritis Rheum.
54:2550–2557. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thomas E, Brewster DH, Black RJ and
Macfarlane GJ: Risk of malignancy among patients with rheumatic
conditions. Int J Cancer. 88:497–502. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mellemkjér L, Andersen V, Linet MS, et al:
Non-Hodgkin's lymphoma and other cancers among a cohort of patients
with systemic lupus erythematosus. Arthritis Rheum. 40:761–768.
1997. View Article : Google Scholar
|
|
36
|
Bernatsky S, Ramsey-Goldman R and Clarke
AE: Revisiting the issue of malignancy risk in systemic lupus
erythematosus. Curr Rheumatol Rep. 7:476–481. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ruiz-Irastorza G, Ugarte A, Egurbide MV,
Garmendia M, Pijoan JI, Martinez-Berriotxoa A and Aguirre C:
Antimalarials may influence the risk of malignancy in systemic
lupus erythematosus. Ann Rheum Dis. 66:815–817. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bernatsky S, Boivin JF, Joseph L, Rajan R,
Zoma A, Manzi S, Ginzler E, Urowitz M, Gladman D, Fortin PR, et al:
An international cohort study of cancer in systemic lupus
erythematosus. Arthritis Rheum. 52:1481–1490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Akerblom HK and Knip M: Putative
environmental factors in Type 1 diabetes. Diabetes Metab Rev.
14:31–67. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Stevens RJ, Roddam AW and Beral V:
Pancreatic cancer in type 1 and young-onset diabetes: Systematic
review and meta-analysis. Br J Cancer. 96:507–509. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zendehdel K, Nyrén O, Ostenson CG, Adami
HO, Ekbom A and Ye W: Cancer incidence in patients with type 1
diabetes mellitus: A population-based cohort study in Sweden. J
Natl Cancer Inst. 95:1797–1800. 2003. View Article : Google Scholar : PubMed/NCBI
|
